Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

NCT06961214 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

960

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: Depemokimab
DRUG: Placebo

Sponsor

GlaxoSmithKline